Resultados de Búsqueda por Autor

artículo

Photoluminescent graphene oxide porous particles in solution under environmental conditions produced by hydrothermal treatment

Publicado por
Rivera Tito H.A., Hernandez-Sosa G., Cucinotta F., Huang X., Quintana Cáceda, María Esther

Publicado 2019

Enlace

Photoluminescent graphene oxide particles (PGOPs) were synthesized by hydrothermal treatment. The relative transmission spectra of the PGOPs in the infrared region between 800 cm?1 and 4000 cm?1 showed frequencies that characterize chemical species such as ethers (C[sbnd]O), ketones (CO[dbnd]), carboxylic acids (COOH), double bonds of carbon (C[dbnd]C) and water (H2O). The emission wavelengths were 568 nm for graphene oxide with green photoluminescence (GOGP) and 634 nm for graphene oxide with orange photoluminescence (GOOP) when excited with a light source of 375 nm. Moreover, the detection of light emission at 600 nm in the photoluminescent excitation (PLE) spectrum is detected with more intensity in GOGP than GOOP due to the presence of groups C[dbnd]C and carboxylates ions ([sbnd]COO?) linked to graphene (GN) and the photon effective emission time according to the decay profile for e...

artículo

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer

Publicado por
Jänne, PA, Planchard, D, Kobayashi, K, Cheng, Y, Lee, CK, Valdiviezo, N, Laktionov, K, Yang, T-Y, Yu, Y, Kato, T, Jiang, L, Chewaskulyong, B, Lucien, Geater, S, Maurel, J-M, Rojas, C, Takahashi, T, Havel, L, Shepherd, FA, Tanaka, K, Ghiorghiu, D, Amin, NP, Armenteros-Monterroso, E, Huang, X, Chaudhry, AA, Yang, JC-H

Publicado 2024

Enlace

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. Methods Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). Results On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were inclu...